Related Experiment Video

Updated: May 20, 2026

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Biomarkers in personalised treatment of renal-cell carcinoma

Shahrokh F Shariat, Evanguelos Xylinas

    The Lancet. Oncology
    |July 5, 2012
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
    08:12

    Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

    Published on: March 14, 2019

    Related Experiment Videos

    Last Updated: May 20, 2026

    The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
    12:22

    The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

    Published on: January 22, 2013

    Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
    08:12

    Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

    Published on: March 14, 2019

    Related Concept Videos

    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

    Articles linked to this work by shared authors, journal, and citation graph.

    SEQUENTIAL INTRAVESICAL GEMCITABINE-DOCETAXEL AFTER BCG FAILURE NON-MUSCLE INVASIVE BLADDER CANCER: ONCOLOGICAL OUTCOMES AND SAFETY PROFILE.

    The French journal of urology·2026

    Role of Second-Look Ureterorenoscopy After Endoscopic Treatment of Upper Tract Urothelial Carcinoma.

    Cancers·2026

    Water Vapor Thermal Therapy with Rezūm Versus Combination Pharmacotherapy for Male Lower Urinary Tract Symptoms due to Benign Prostatic Obstruction: 1-Yr Results From a Prospective, Multicenter, Pragmatic Randomized Controlled Trial (VAPEUR-RCT).

    European urology focus·2026

    Artificial intelligence and predictive tools in non-muscle invasive bladder cancer: a narrative review of current insights and advances.

    Translational andrology and urology·2026

    Molecular Profiling of Urothelial Bladder Cancer: Bridging Tumor Biology and Clinical Decision-making.

    European urology oncology·2026

    Prognostic impact of tumor size in low-risk upper tract urothelial carcinoma: A multi-institutional analysis.

    The French journal of urology·2026

    Invasive interval breast cancer rates after digital breast tomosynthesis plus synthesised mammography versus digital mammography screening (TOSYMA): 24-month follow-up of the multicentre, open-label, randomised, controlled, superiority trial.

    The Lancet. Oncology·2026

    Neoadjuvant niraparib monotherapy for unresectable, homologous recombination deficiency-positive, high-grade serous ovarian cancer (NANT): a multicentre, single-arm, phase 2 trial.

    The Lancet. Oncology·2026

    Reporting health-related quality of life in randomised clinical trials evaluating adjuvant systemic therapy: recommendations of Common-Sense Oncology and the European Organisation for Research and Treatment of Cancer.

    The Lancet. Oncology·2026

    Cancer and the microbiome: from association to intervention.

    The Lancet. Oncology·2026

    Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer (CHN HYPOPMRT): 10-year outcomes from a randomised, non-inferiority, open-label, phase 3 trial.

    The Lancet. Oncology·2026

    Global burden of cancer attributable to infections in 2024: a worldwide incidence analysis.

    The Lancet. Oncology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us